Overview of resistance mechanisms to RAF inhibitors in mutant BRAF melanoma. Mutant BRAF melanoma spreads to the brain in nearly 50% of patients, which carries a poor prognosis and life expectancy of ...

Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapies, cancer genomics, using AI to personalize cancer treatment, improving diagnosis of hard-to-treat ...

As we have reported, the BRAF and RAS mutant tumors are more sensitive to ERK pathway inhibition than the RAF/RAS wild type tumors. We are now investigating the biochemical actions and anti-tumor ...

This inhibits MEK and also suppresses feedback reactivation of RAF activity. BRAF and MEK inhibitor combinations already show that dual blockade of these signalling nodes can work better than ...

Currently, the only program in the clinic for ERAS is naporafenib, a small molecule inhibitor of the "B" and "C" variants of the Raf kinase. This is similar in principle to well-known B-Raf ...

In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...

MAPK pathway inhibitors are currently utilized for the therapy of malignant metastatic melanoma. They include RAF inhibitors, such as sorafenib and vemurafenib, or MEK inhibitors such as ...

A novel topical formulation of a BRAF inhibitor significantly reduced acneiform rash associated with anti–epidermal growth factor receptor (EGFR) therapies in patients with colorectal cancer ...

Mutations in the RAS-RAF-MEK-ERK pathway that drive many forms of human malignancies. In particular, the serine/threonine kinase BRAF is mutated in ~8% of all cancers. Targeted inhibitors have been ...